Current

Studies

Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW)

The ACT NOW Program

Funded through The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, the ACT NOW research program aims to test the ways babies with NOWS are assessed, treated, and followed long-term, so that the infants can get the best possible care.


The program is a collaborative effort of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) and the ECHO IDeA States Pediatric Clinical Trials Network (ISPCTN).


The importance of NOWS research

When a woman uses opioids during pregnancy, her baby may be born with a condition called Neonatal Opioid Withdrawal Syndrome (NOWS). The withdrawal symptoms for these babies can include tremors; excessive crying and irritability; and problems with sleeping, feeding, and breathing.


There are currently few standard, evidence-based treatments for NOWS, and doctors and researchers still don’t know much about the long-term effects of this condition.

ACT NOW Research Studies

ECHO researchers are part of two current ACT NOW studies, and participated in another that is now complete. These studies launched in Spring 2021 and aim to determine the best ways for hospitals to care for babies with NOWS.


SPeCTr participated in ACT NOW CE and is participating in Eat, Sleep, Console and Weaning. For Eat, Sleep, Console, we have two sites -- University of Kansas Medical Center and Advent Health Shawnee Mission. For Weaning, we have one site at University Health.

Study Summary:

BREATHE is a multi-center ECHO ISPCTN trial that aims to determine if indoor air filtration improves respiratory symptoms in children under 12 months of age who have been hospitalized for bronchiolitis. After two weeks of baseline indoor air quality measurements, the caregiver of the child participant installs an air filtration unit intervention with or without HEPA filters (in the child’s sleep space and a common room). Children are followed for respiratory outcomes for approximately 6 months. The study’s enrollment target: 228


BREATHE is designed to reduce barriers to participation for rural participants in that there will be no required study visits to a distant study site, and all study activities and data collection will be conducted remotely. Participants will be identified in hospitals in ISPCTN states, maximizing the chances that rural and medically underserved populations are represented.


SPeCTr's site for BREATHE is in Wichita. We enrolled 11 participants.


NCT #05615870

Improving Pediatric COVID-19 Vaccine Uptake

 Using an mHealth Tool (MoVeUP)

Questions?

For more information, email us at SPeCTr@kumc.edu or call us directly at (913) 588-6393.

Share by: